Renalytix Plc's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Renalytix Plc's ROA in the first quarter of 2025?
Renalytix Plc recorded a cumulative net loss of $-28 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -373.77%.

However, within the Healthcare sector 983 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 4963, from total ROA ranking in the fourth quarter of 2024 at 4986.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) I. Quarter	(Jun 30 2024) IV. Quarter	(Mar 31 2024) III. Quarter	(Dec 31 2023) II. Quarter	(Sep 30 2023) I. Quarter
Y / Y Total Assets Change	-75.03 %	-75.74 %	-79.66 %	-65.59 %	-47.15 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-28	-33	-72	-76	-113
Return On Assets (TTM)	-373.77 %	-301.77 %	-425.6 %	-311.22 %	-386.34 %
RNLX's Total Ranking	# 4963	# 4986	# 5112	# 5827	# 5290
Total Assets (TTM) in million	5	7	8	10	19
Seq. Total Assets Change	-36.05 %	-4.06 %	-21.95 %	-47.86 %	-37.87 %
Seq. Net Income Change	-	-	-	-	-

RNLX's 5 Years Annual ROA >> Back to RNLX Management Effectiveness >> Compare RNLX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 39
Sector	# 984
Overall	# 4861

Return On Assets Statistics
High	Average	Low
-43.42 %	-266.28 %	-410.11 %
(Jun 30 2021)		(Mar 31 2024)

News about Renalytix Plc Return on Assets ROA

Revolutionizing Kidney Disease Management: KidneyIntelX Recognized in Final KDIGO 2024 Clinical Guideline

Chronic Kidney Disease (CKD) affects millions of people worldwide and imposes a significant burden on healthcare systems globally. As we enter a new era of personalized medicine, risk prediction and tailored treatment plans are crucial in managing this complex and widespread condition. The inclusion of KidneyIntelX in the Final KDIGO 2024 Clinical Guideline for CKD is a landmark moment, as it highlights the imperative need for advanced risk assessment tools in optimizing patient care and reducing the risk of progression to end-stage renal disease (ESRD). This article explores the significance of this development and the potential impact it holds for the future.
Risk Prediction and Personalized Treatment:
The Final KDIGO 2024 Clinical Guideline emphasizes the importance of risk prediction and personalized treatment to mitigate the challenges posed by CKD. Traditionally, CKD management focused on categorizing patients into different stages based on estimated glomerular filtration rate (eGFR) and albuminuria levels. However, this approach fails to consider the heterogeneity and complexity of the disease. With the integration of KidneyIntelX, a proprietary platform developed by Renalytix AI, physicians gain access to cutting-edge technology that combines artificial intelligence and biomarker analysis to predict an individual s risk of disease progression and provide tailored treatment plans.

Financial Statements
Renalytix Plc's Assets	$ 5 million	RNLX's Balance sheet
Renalytix Plc's Income	$ -5 million	Quarterly RNLX's Income Statement
RNLX's Income by Division		See RNLX's Income by Division

Annual Return On Assets	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021	(Jun 30 2020) FY 2020
Y / Y Total Assets Change	-75.74 %	-32.84 %	-34.48 %	311.64 %	-
Total Assets in million	7	31	46	70	17
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-33	-46	-45	-34	-10
Annual Return On Assets	-448.05 %	-148.17 %	-98.78 %	-48.77 %	-57.93 %

RNLX's 5 Years Annual ROA >> Back to RNLX Management Effectiveness >> Compare RNLX ROA to its Competitors

More Return On Assets Ratios
RNLX's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RNLX's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RNLX's Competitors
Subscribers only: Roa for Renalytix Plc's Suppliers
Subscribers only: Return On Assets for RNLX's Customers

You may also want to know
RNLX's Roi	RNLX's Inventory Turnover Ratio	RNLX's Growth Rates	RNLX's Dividend Comparisons
	RNLX's Profitability Ratios	RNLX's Asset Turnover Ratio	RNLX's Dividend Growth
RNLX's Roe	RNLX's Valuation Ratios	RNLX's Financial Strength Ratios	RNLX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-08-31T16:10:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.